Market Size of Heart Attack Diagnostics Industry
![Heart Attack Diagnostics Market Size](https://s3.mordorintelligence.com/heart-attack-diagnostics-market/1619696954736_heart-attack-diagnostics-market_Market_Summary.webp)
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 7.90 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Heart Attack Diagnostics Market Analysis
The global heart attack diagnostics market is expected to register a CAGR of 7.9% during the forecast period (2021 - 2026).
The COVID-19 pandemic has significantly impacted the heart attack diagnostics market. There is an increased risk for people suffering from heart diseases to contract the virus, especially those prone to heart attacks, and there is a high probability of death if the virus is not diagnosed on time. Moreover, some of the early symptoms of COVID-19 are aligned with heart attacks, like chest pain, nausea, fatigue, and trouble in breathing. In July 2020, a report published by researchers from the University of Alberta Faculty of Medicine and Dentistry discovered a new blood test for predicting heart attacks in patients with COVID-19. This study proved the relationship between the risk of COVID-19 and people having cardiovascular diseases.
According to a repoty by the World Health Organization, cardiovascular diseases are the main cause of deaths worldwide, and four out of five deaths occur due to cardiovascular diseases like heart attack and strokes. Furthermore, over 13 million deaths occur in low- and middle-income countries every year, and of these, 85% are due to heart attack and stroke. A report from the American Heart Association says that by 2035, around 45% of Americans may have some kind of heart disease (mainly heart attack), which may be a major driving force for the heart attack diagnostic market. The major factors contributing to the high number of cardiovascular diseases are hypertension, high blood cholesterol, and smoking. The proven methods for detecting heart attacks are electrocardiograms, blood tests, angiograms, and computerized cardiac tomography. Recently, the US Food and Drug Administration approved a new high-sensitivity test for a protein, Troponin, for the detection of heart attacks, in which Roche and Abbott are the major players.
Although many factors are likely to drive this market to new levels, a few restraining factors, like the high cost and the lack of awareness, may create hindrances in its path. As this market functions on a global level and low-income countries are involved, diagnostic kits need to be within the budget of the people, and these people should be aware of them. For instance, the Roche Trop T Sensitivity test kit is available for about USD 52 (2020) in India, which is out of reach for many low-income families and not easily available.
Heart Attack Diagnostics Industry Segmentation
As per the scope of the report, the heart attack diagnostics market may see many innovations, which may reduce the time for detection from seven hours to two hours or less, just like troponin tests that not only save time, but also reduce the chance of death due to cardiac arrest. The heart attack diagnostics market is segmented by test (electrocardiogram, blood tests, angiogram, computerized cardiac tomography, and other tests), end user (hospitals, ambulatory surgical centers, diagnostics centers, and other end users), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America).
By Test | |
Electrocardiogram | |
Blood Tests | |
Angiogram | |
Computarized Cardiac Tomography | |
Other Tests |
By End User | |
Hospitals | |
Ambulatory Surgical Centers | |
Diagnostic Centers | |
Other End Users |
By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Heart Attack Diagnostics Market Size Summary
The heart attack diagnostics market is poised for significant growth, driven by the increasing prevalence of cardiovascular diseases globally. The market is influenced by the rising incidence of heart attacks, particularly in low- and middle-income countries, where factors such as hypertension, high cholesterol, and smoking are prevalent. The COVID-19 pandemic has further underscored the importance of timely diagnostics, as individuals with pre-existing heart conditions face heightened risks. Innovations in diagnostic technologies, such as the development of rapid blood tests and enzyme-based techniques like the Troponin T diagnostic kit, are expected to enhance early detection and treatment outcomes. These advancements are particularly crucial in regions with limited access to advanced healthcare facilities, where portable and cost-effective solutions can make a significant impact.
North America is anticipated to lead the heart attack diagnostics market, supported by robust healthcare infrastructure and a high rate of innovation. The region's focus on developing advanced diagnostic tools aligns with the growing need to address heart disease, which is a leading cause of mortality. Meanwhile, the market in developing countries is expected to expand through the adoption of rapid blood tests, which offer quick results and can be administered in various settings, including mobile healthcare units. The competitive landscape is characterized by the presence of key players such as Siemens Healthcare, Schiller AG, and Roche, who are actively involved in introducing new technologies and expanding their product offerings. As the market evolves, the integration of artificial intelligence and other advanced technologies is likely to play a transformative role in predicting and managing heart attack risks.
Heart Attack Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Technological Advancements
-
1.2.2 Significant Rise in Cardiovascular Diseases
-
1.2.3 Increase in Quality of Life
-
-
1.3 Market Restraints
-
1.3.1 Expensive Diagnostics Products
-
1.3.2 Lack of Skilled Workforce in the Hospitals and Other Areas
-
-
1.4 Industry Attractiveness - Porter's Five Force Analysis
-
1.4.1 Bargaining Power of Buyers/Consumers
-
1.4.2 Bargaining Power of Suppliers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Test
-
2.1.1 Electrocardiogram
-
2.1.2 Blood Tests
-
2.1.3 Angiogram
-
2.1.4 Computarized Cardiac Tomography
-
2.1.5 Other Tests
-
-
2.2 By End User
-
2.2.1 Hospitals
-
2.2.2 Ambulatory Surgical Centers
-
2.2.3 Diagnostic Centers
-
2.2.4 Other End Users
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Heart Attack Diagnostics Market Size FAQs
What is the current Heart Attack Diagnostics Market size?
The Heart Attack Diagnostics Market is projected to register a CAGR of 7.90% during the forecast period (2024-2029)
Who are the key players in Heart Attack Diagnostics Market?
Siemens Healthineers, Schiller AG, GE Healthcare, Hitachi Medical Systems and F Hoffmann-La Roche Ltd are the major companies operating in the Heart Attack Diagnostics Market.